Therefore, to inhibit the PRMT5/MSI2/c-MYC/BCL-2 axis we proposed two drug combination strategies; the first one consists of targeting PRMT5 in combination with a MSI2 inhibitor, which results in loss of c-MYC and BCL-2 translation cell-cycle regulators in lymphoma cells. Here, BCL2 is linked to lymphoma.